Earlier this week, Calibr-Skaggs announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2, 105-patient study in Crohn’s disease. CLF065 is the first long-acting GLP-2 analog to enter Phase 2 trials specifically for IBD, with a pharmacology that supports the potential for once-monthly dosing intervals. “For people with IBD, today’s therapies focus almost entirely on suppressing inflammation, without repairing the damaged intestinal lining that drives the disease," says @AmyLightnerMD, chief medical officer at Calibr-Skaggs and principal investigator of the pouchitis study. "CLF065 is designed to both actively regenerate and repair the gut epithelium, thereby complementing anti-inflammatory agents to change the IBD treatment paradigm.” More: ow.ly/N9ux50Zbc6P

Current therapies for inflammatory bowel disease (IBD) primarily focus on suppressing inflammation. But what if we could repair one of the underlying drivers of disease itself? Researchers at Calibr-Skaggs are developing CLF065, a potential first-in-class regenerative medicine designed to restore epithelial barrier function—the protective intestinal lining that regulates what passes from the gut into the body. CLF065 is designed with a dual mechanism of action: supporting barrier integrity and stimulating regeneration of the gut lining. A Phase 2 clinical trial has recently launched in chronic pouchitis, a painful inflammatory condition that can develop in some people with IBD following surgery. In addition, an Investigational New Drug (IND) application has been submitted to support a Phase 2 trial in Crohn's disease. Learn how regenerative medicine could help shift the treatment paradigm from managing symptoms to repairing the tissue damage at the root of disease. More: ow.ly/plfR50Zabqq

At Scripps Research and Calibr-Skaggs, scientists are developing regenerative medicine therapies designed to help the body repair itself from within. Researchers are exploring new approaches for heart failure, IPF, IBD, age-related macular degeneration and more. More: ow.ly/K8Zz50Z8cPS

Biomedical research has produced many of the discoveries that underpin modern medicine, but turning those findings into real treatments—and maintaining the research enterprise behind them—requires new approaches. In last week's free Front Row lecture, Scripps Research President and CEO Peter Schultz described how the institute is building a nonprofit model that brings basic science and translational research together to move promising ideas toward medicines more effectively. He highlighted advances spanning aging, artificial intelligence (AI) and global health while also making the case for a more sustainable way to support innovative science. Watch the full lecture now at ow.ly/qA6Q50YQNMv #ScrippsResearch #Nonprofit #Biomedial #Research #Science #Biotech

It is time. 5/10/26. The Feud Comes To Tampa. #ASCRS26 #TheFeud @ASCRS_1 @Thomascurran27 @SeanLangenfeld @DavidLiskaMD @Averywalker21 @SoniaRamMD @valevilchezp @AmyLightnerMD @sarahchoiMD @Lilian_ChenMD

Amazing to see colleagues recognized for the translational work being done #1 in US in biological science …translation to patient impact is seen every day

Scripps Research welcomes healthcare innovator Joe Kiani to its Board of Directors. Kiani brings decades of experience in patient safety and public service, and is the founder of Willow Laboratories and Masimo, known for advancing noninvasive patient monitoring technologies. More: ow.ly/pHut50YomVJ

Not all matters of the heart are metaphorical, including a damaged one ❤️‍🩹 Scientists across Scripps Research, working with the Calibr-Skaggs Institute for Innovative Medicines, are advancing regenerative medicine approaches that could help injured heart tissue repair itself—moving beyond symptom management toward restoring function. This work, led in part by @MichaelBollong and Peter Schultz, focuses on first-in-class small molecules that activate pathways to stimulate new cardiac muscle growth after injury. These efforts are part of a broader pipeline aimed at repairing tissues of the heart, lungs, gut, and more. The image below shows cardiac damage after myocardial infarction (left) and how a regenerative medicine approach developed at Scripps Research stimulates repair by expanding new cardiac muscle cells (right). The research was featured in @WSJ, highlighting the potential of regenerative approaches to reshape treatment for aging-related diseases. Learn more in the comments below.

Two years ago today, San Diego officially declared February 15, 2024, “Scripps Research Day” in recognition of the institute’s 100 years of scientific discovery. The day remains a meaningful milestone in our history and a reminder of how deeply our science has changed lives.

A single gift from Ellen Browning Scripps helped launch Scripps Research. Since then, 18 FDA-approved drugs have originated within our labs, improving the lives of people around the world. This #GivingTuesday, you can also be a part of that legacy. Visit scripps.edu/givingtuesday.

Long before a medicine reaches a pharmacy, hospital, or clinic, it begins inside a lab like those at Scripps Research. Here, scientists spend years turning discoveries into new therapies, leading to more than 15 FDA-approved treatments that have helped people worldwide. Learn more: ow.ly/aHZs50XjnU7

Celebrating #NationalPAweek! Could not be more grateful for getting to work with @AlexSilberstein. She had been an incredible addition to the team and is one of the most thoughtful, hard working, empathetic, and thought partner PAs! Thank you!!

Discussing #crohnsdisease #perianalfistula at #IBDCuttingEdge2025 with a phenomenal GI, surgery, patient panel…consider which medical therapy after you drain a personal abscess and get source control. What is the best agent? #scrippsresearch #calibrskaggs

Fantastic session on management of dysplasia in #IBD…surveillance critical and consider surgery with HGD, multifocality, PSC, and inadequate surveillance (ie psuedopolyps) thank you @IBDMD @tracyhull #IBDCuttingEdge2025

📣 We’re just days away from #IBDCuttingEdge2025 —a three-day CME event exploring the future of IBD care: translational science, clinical trials, surgery, and multidisciplinary models led by top experts. Join us: 📅 Sept 19–21, 2025 📍Coronado, CA 🎟️ ow.ly/v6qx50VFLVm

Thank you to #scrippsresearch #calibr-skaggs to continuing to push #innovation and #education for #IBD we are fortunate to have a community of scientists here who are committed to finding a cure for our patients

Next week, Scripps Research scientists @AmyLightnerMD, @MichaelBollong & Arnab Chatterjee will speak at #IBDCuttingEdge2025, sharing insights on regenerative medicine, clinical trials, and drug discovery in IBD. Join us next week, Sept 19–21 | 📍 Coronado, CA 🎟️ Register now: ow.ly/xPsK50VFU8L

What does it take to turn a scientific discovery into a life-changing medicine? At Science in Action, guests had the chance to find out, getting an up-close look at how scientists at Scripps Research and its drug development division, the Calibr-Skaggs Institute for Innovative Medicines, translate early-stage discoveries into potential FDA-approved therapeutics. Following a Front Row lecture by Travis Young, PhD (@CARTCellTherapy), vice president of biologics at Calibr-Skaggs, attendees explored the full discovery and development pipeline, from high-throughput screening of small molecules using 384-well and 1536-well plates to candidate selection, IND-enabling studies, and the eventual path to clinical trials. Guests got to see how promising compounds discovered right here at Scripps Research advance through each stage of the pipeline—and how Calibr helps bridge the gap between scientific innovation and real-world impact for patients around the globe. To see Science in Action in person, visit frontrow.scripps.edu and be sure to save the dates for our upcoming Front Row lectures, where guests can meet the scientists from the presenting lab, take part in hands-on demonstrations, see the tools they use in their research, and ask questions sparked by the lecture.

Perineal ultrasound at our inaugural #crohns #MDT #perianalfistula clinic…joint discussions with the patients around decision making, bedside imaging and new biomarker collection! @GGKonijeti @ScrippsHealth @scrippsresearch

Outcome of transanal advancement flap repair (TAFR) as salvage therapy after failed ligation of intersphincteric fistula tract (LIFT)—A proposed algorithm after failed LIFT onlinelibrary.wiley.com/doi/… @ColorectalDis open access